News

Clavis' 2nd lead failed
Enlarge image

BusinessNorway

Clavis' 2nd lead failed

03.04.2013 - Clavis Pharma has become a target for a take-over after its cancer drug delivery technology failed proof-of-concept for the second time.

In November, US partner Clovis Oncology said it will terminate its partnership with the Norwegian drug developer after CP-4126 , a liposomal formulation of the chemotherapeutic gemcitabine, failed to prove superiority to the original drug in a Phase IIb study. Yesterday, the company’s second lead, elacytarabine, fell through in a pivotal Phase III study on 380 patients with refractory blood cancer AML.

Median survival in the elacytarabine arm was 3.5 months, compared to 3.3 months in the control arm. Adverse events were comparable between the two arms, and no meaningful differences were observed in any subgroup analyses. “We will review the strategic options for the company during the coming weeks, and shareholders will be informed about the alternatives available at a later date. Immediate steps will be taken to minimise our expenditure going forward, while caring for those patients who are still benefiting from elacytarabine,“ said CEO Olaf Hellboe.

All studies with the compound have been suspended. Hellboe announced that Clavis has a short-list of private Scandinavian firms that may be interested in a take-over of the public company. "We have taken two products all way through development with lipid technology and both failed in the big final test," said Helleboe. "That means it will be very difficult to justify putting huge investments in another product with the same technology.“

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/clavis-2nd-lead-failed.html

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

PoliticsBelgium

08.01.2015 Belgian cell therapy specialist Cardio3 Biosciences joins the immuno-oncology arena with the acquisition of Celdara Medical's cancer division Oncyte for US$180m.

PoliticsIrelandEU

06.01.2015 With the aim to utilise Ireland’s many natural resources and keep abreast of the latest EU developments in bioeconomy, a multi-disciplinary team has been funded to maximise national income, exports and job creation related to Ireland’s bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products